Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:
“ASCO26 Rapid Oral Abstract Presentation by Solange Peters
ROSETTA Lung-02: Pumitamig (PD-L1×VEGF-A bsAb) + Chemo in 1L NSCLC
- ORR 70.0%
- NSQ ORR 66.7%, SQ ORR 73.7%
- Active across all PD-L1 levels.”
Title: Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy in 1L NSCLC
Authors: Solange Peters, Youngjoo Lee, Mustafa Erman, Stephen V. Liu, Benjamin J. Solomon, Terufumi Kato, Shun Lu, Sanjay Popat, Ulug M. Gunaydin, René Bartz, Vikesh Patel, Kevin Tsai, Li Li, Uchechukwu C. Dimkpa, Claudia Nanette Gann, Aurora OBrate, Ilhan Celik, Özlem Türeci, Ugur Sahin, Byoung Chul Cho
Read the Full Abstract.
Other articles featuring Dr. Horinouchi on OncoDaily.
